Delivered at 14:00 on November 30, 3rd year of Reiwa

Press release materials

Press Club, Honmachi Press Association, Nagoya Education Press Association)

A venture company was established aiming at the practical application of research results.

Translated by https://www.folliclethought.com/

Government of the Promising Seeds Development Project of the Institute of Technology (KISTEC) and the Ministry of Education, Culture, Sports, Science and Technology "Regional Innovation Ecosystem Formation Program"[*1] Two venture companies (B-MED) for the purpose of social implementation of the results of research projects underway in Co.[*2], TrichoSeeds Co., Ltd.[*3]) was established. B-MED Co., Ltd. aims to put the results of joint research between KISTEC, Tokyo Medical and Dental University and Tokai National University Organization Nagoya University, and Tricho Seeds Co., Ltd. to practical use. In the future, we plan to promote the consolidation of intellectual property rights at venture companies and establish the system necessary for commercialization. Each institution will continue to provide support for commercialization as soon as possible.

<Comments from the producer of the regional innovation ecosystem formation program Marai Business> The technologies of B-MED and TrichoSeeds, which were established this time, are epoch-making technologies that can meet the unmet medical needs of diabetic patients and alopecia patients, respectively. In the medium to long term, sales of several hundred billion yen / year are expected. So far, KISTEC and each university have promoted joint research and development to secure technological superiority. With the establishment of this venture, we will continue to do our best to survive the fierce competition for practical application, such as shifting to practical development led by domestic medical device companies and pharmaceutical companies as soon as possible.

* 1 Regional Innovation Ecosystem Formation Program

“Healthcare New Frontier” Leading Project

from Kanagawa Kanagawa Prefecture and KISTEC jointly applied for the project and adopted it in FY2018. To realize the "Healthcare New Frontier" that will take on the challenge of a super-aging society, we will implement it under a commercialization support system centered on universities and KISTEC, focusing on the creation and growth of leading ventures in Kanagawa. We aim to realize a unique innovation ecosystem.

* 2

President and CEO of B-MED Co., Ltd .: Ryo Matsumoto (KISTEC Project Leader / Associate Professor, Tokyo Medical and Dental University) Established: November 11, 2021

Business description: Research and development of medical equipment (diabetes treatment equipment, etc.) Management of intellectual property rights, etc.

* 3 TrichoSeeds Co.

President: Junji Fukuda (KISTEC Project Leader / Professor, Yokohama National University) Established: November 1, 2021

Business: Research and research related to hair and skin regeneration medicine Development, management of intellectual property rights, etc.

[Contact]

<Reporting>

Kanagawa Prefectural Institute of Industrial Technology (KISTEC)

Research and Development Department E-mail:rep-kenkyu@kistec.jp TEL:

044-819-2031 FAX: 044-819-2026

Public Relations and Public Relations Section, President's Office, General Affairs Planning Department, Yokohama National University

E-mail:press@ynu.ac.jp TEL: 045-339-3027 FAX: 045-339-3179

Public Relations Section, General Affairs Secretary Division, General Affairs Department, Tokyo Medical and Dental University

E-mail:kouhou.adm@tmd.ac.jp TEL: 03-5803-5833 FAX: 03-5803-0272

National University Corporation Tokai National University Organization Nagoya

University Administration Department General Affairs Division Public Relations Office

E-mail:nu_research@adm.nagoya-u.ac.jp TEL: 052-789-3058 Fax: 052-789-2019

Attachment Material Ministry of Education, Culture, Sports, Science and Technology Regional Innovation Ecosystem Formation Program Overview

<Business Overview>

The Ministry of Education, Culture, Sports, Science and Technology's Regional Innovation Ecosystem Formation Program is "Social Impact" By promoting commercialization projects that contribute to the growth of national wealth as well as the growth of the region, we aim to form a Japanese-style innovation ecosystem and realize regional revitalization. " This program aims to form a commercialization project, an innovation ecosystem, and function R & D projects for commercialization that have the potential to become an indispensable success model for the formation of an innovation ecosystem.

sustainablyIt consists of a foundation building project to build the infrastructure necessary for. In the "Healthcare New Frontier" leading project from Kanagawa, we have positioned the two projects that led to the establishment of the venture company as commercialization projects, and have been working toward commercialization.



Figure Overview of "Healthcare New Frontier" Leading Project from Kanagawa (as of Reiwa 3)

<Introduction of Commercialization Project>

1. Commercialization Project 1 "Development of Autonomous Next-Generation Artificial Pancreas by Just Sticking"

KISTEC Project Name : Promising seeds development project "Paste-only artificial pancreas" project Project leader: Ryo Matsumoto (Associate Professor, Institute of Biomaterials Engineering, Tokyo Medical and Dental University) Sub-leader: Takayoshi Suganami (Professor, Institute of Environmental Medicine, Tokai National University Organization)

"Machine" We aim to commercialize a minimally invasive microneedle-type insulin patch = "just stick artificial pancreas" that can automatically administer insulin according to the blood glucose level without being required and can be used continuously for one week.

Phenylboronic acid (PBA) -containing gels swell at high glucose concentrations and shrink at low glucose concentrations to form a wall of shrinkage layers on the surface called the "skin layer"

Dehydration insulin that utilize this phenomenon from the network structure of the swollen gel during insulin



prevents the release of insulin molecules during hyperglycemia. (Figure 2).

Figure 1 Prototype

Figure 2 Operating Principle

2. Commercialization Project 2 "Development of Mass Preparation Innovation Technology for Regenerated Hair" KISTEC Project Name: "Development of Mass Preparation Innovation Technology for Regenerated Hair"

Project Leader: Junji Fukuda (Yokohama National University Graduate School) Professor, Graduate School of Engineering)

By mixing epithelial and mesenchymal cells derived from hair follicles into a uniquely developed culture vessel, a large amount of transplanted tissue (hair follicle primordia) required for transplantation is produced by the self-organization phenomenon of cells. By establishing "cell proliferation, preparation of transplanted tissue, and precision transplantation", which are the three technologies necessary for hair regrowth medicine, and by achieving the proof of concept using human cells, based on the unique culture technology that can be prepared in Japan. We are aiming to commercialize hair regrowth medicine (Fig. 2), which has excellent safety and cost and enables

the fundamental treatment of alopecia, which replaces the current treatment of hair transplantation.



Fig. 1 Hair regenerated after transplantation to mice Fig. 2 Outline and necessary technology of hair regenerative medicine